Reclast news from FiercePharma
NewsFDA: Osteo meds can cause severe pain
Oh, the irony. The very drugs prescribed to strengthen bones can spark stabbing limb and joint pain, according to a reminder from the FDA. Info about the possibility of those pains--which can be Read more...
Novartis gains Aclasta, loses Prexige
From the good news, bad news file: Novartis got the EU's approval to sell its new osteoporosis drug Aclasta, known in the U.S. as Reclast. Reclast Read more...
Novartis drug cuts hip-fracture deaths
Big kudos to the Novartis osteoporosis drug Reclast: A New England Journal of Medicine study showed that patients with broken hips were more likely to survive if they were given a yearly dose of the Read more...
| Press ReleasesPRESS RELEASE: First Osteoporosis Study in Patients with Hip Fracture Finds Aclasta-reclast Prevents Fractures First Osteoporosis Study in Patients with Hip Fracture Finds Once-yearly Aclasta-reclast Prevents Additional Fractures and Improves Survival Study of more than 2,100 patients who suffered a hip Read more... |
Get more Reclast coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight